EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthesis and 64 Cu‐Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold

Marie M Le Roy iD, Patricia Le Saëc iD, Michel Chérel iD, Alain Faivre-Chauvet iD, Thibault Troadec iD, Raphaël Tripier iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202500243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Marie M Le Roy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Brest, UMR CNRS 6521 CEMCA, 6 avenue Le Gorgeu, 29200, Brest, France. Hauptthemen laut MEDLINE: Copper Radioisotopes, Radiopharmaceuticals, Receptors, CXCR4, Heterocyclic Compounds. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ligue Contre le Cancer, Région Bretagne - Ligue contre le Cancer, SIRIC ILIAD Nantes-Angers-INCA-DGOS-Inserm 12558 grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CXCR4 is a transmembrane receptor overexpressed in a large variety of cancer cells. In addition to classical antibody‐ and peptide‐targeting for the development of positron emission tomography (PET) radiopharmaceuticals, this receptor possesses a range of small organic inhibitors that can be exploited. These are based mainly on nitrogen‐rich scaffolds, such as AMD070, and cyclic polyamines, such as cyclam, in the AMD3100 skeleton. The latter has been explored as a direct 64 Cu chelator, but examples of CXCR4 PET imaging with small organic targeting units are still scarce in the literature. Herein, the synthesis of two novel CXCR4‐directed radiopharmaceuticals is described, combining the AMD070 scaffold as a targeting unit and bifunctional te1pa macrocycle as a strong 64 Cu chelator. The synthesis of the conjugates and optimization of 64 Cu‐radiolabeling are presented, opening the way for future in vitro and in vivo studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Copper RadioisotopesRadiopharmaceuticalsReceptors, CXCR4Heterocyclic CompoundsHumansPositron-Emission TomographyCyclamsChelating AgentsBenzylaminesMolecular Structure

Stichwörter der Autor:innen

CXCR4chelatorscoordinationcopper‐64positron emission tomography imaging

Substanzen

Copper RadioisotopesRadiopharmaceuticalsReceptors, CXCR4CyclamsCopper-64Heterocyclic CompoundsChelating AgentsBenzylaminesplerixaforCXCR4 protein, human

Autor:innen und Institutionen

  • Univ. Brest, UMR CNRS 6521 CEMCA, 6 avenue Le Gorgeu, 29200, Brest, France.
  • Univ. Angers, Nantes Univ., Inserm, CNRS, CRCI2NA, CHU Nantes, F-44007, Nantes, France.
  • Institut de Cancérologie de l'Ouest, F-44800, Saint-Herblain, France.
  • Nuclear Medicine Department, University Hospital, 44000, Nantes, France.

ORCID-Profile: Marie M Le Roy, Patricia Le Saëc, Michel Chérel, Alain Faivre-Chauvet, Thibault Troadec, Raphaël Tripier

Förderung

  • Ligue Contre le Cancer
  • Région Bretagne - Ligue contre le Cancer
  • SIRIC ILIAD Nantes-Angers-INCA-DGOS-Inserm 12558 grant
  • French National Agency for Research "Investissements d'Avenir"
  • NExT initiative "Nantes Excellence Trajectory"
  • "Programme d'Investissements d'Avenir (PIA2)"
  • Région Bretagne

Zitieren

APA

Le Roy, M. M., Le Saëc, P., Chérel, M., Faivre-Chauvet, A., Troadec, T., & Tripier, R. (2025). Synthesis and 64 Cu‐Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold. ChemMedChem. https://doi.org/10.1002/cmdc.202500243

Vancouver

Le Roy MM, Le Saëc P, Chérel M, Faivre-Chauvet A, Troadec T, Tripier R. Synthesis and 64 Cu‐Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold. ChemMedChem. 2025. doi:10.1002/cmdc.202500243

BibTeX
@article{LeRoy2025,
  author = {Le Roy, Marie M and Le Saëc, Patricia and Chérel, Michel and Faivre-Chauvet, Alain and Troadec, Thibault and Tripier, Raphaël},
  title = {Synthesis and 64 Cu‐Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202500243}
}
Kostenlos starten →